Self-injectable epinephrine — Competitive Intelligence Brief

Self-injectable epinephrine (Self-injectable epinephrine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Adrenergic agonist. Area: Allergy and Anaphylaxis.

phase 3 Adrenergic agonist Adrenergic receptors Allergy and Anaphylaxis Small molecule

Target snapshot

Self-injectable epinephrine (Self-injectable epinephrine) — Merck Sharp & Dohme LLC. Self-injectable epinephrine works by stimulating the body's natural response to anaphylaxis through the release of epinephrine.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Self-injectable epinephrine TARGET	Self-injectable epinephrine	Merck Sharp & Dohme LLC	phase 3	Adrenergic agonist	Adrenergic receptors
Tudorza Pressair	ACLIDINIUM BROMIDE	Covis	marketed	Anticholinergic	M3 receptors, beta 2 -adrenergic receptors	2012-01-01
ACLIDINIUM	ACLIDINIUM		marketed		M3 receptors, beta 2 -adrenergic receptors	2012-01-01
ISOPROTERENOL	ISOPROTERENOL		marketed	Beta-adrenergic agonist	beta-adrenergic receptors	1956-01-01
PHENTOLAMINE	PHENTOLAMINE		marketed		alpha-adrenergic receptors	1952-01-01
Norepinephrine Bitartrate In 5% Dextrose	NOREPINEPHRINE	Pfizer	marketed	Catecholamine	alpha-adrenergic receptors, beta-adrenergic receptors	1950-01-01
amiodarone amiodarone	amiodarone amiodarone	National Heart, Lung, and Blood Institute (NHLBI)	marketed	Class III antiarrhythmic agent	Potassium channels (hERG), sodium channels, beta-adrenergic receptors, calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Adrenergic agonist class)

1. Amphastar Pharmaceuticals, Inc. · 1 drug in this class
2. Merck Sharp & Dohme LLC · 1 drug in this class